

# PSORIASIS

CHRONIC, NON-COMMUNICABLE DISEASE OF THE IMMUNE SYSTEM

125 MILLION PEOPLE ARE AFFECTED WORLDWIDE

Please visit [www.ifpma.org](http://www.ifpma.org) for more information.



## PHYSICAL SYMPTOMS


Up to 90%

of patients suffer from symptoms which can be painful, disfiguring and disabling



## PSYCHOLOGICAL IMPACT

The psychosocial impact of psoriasis can be devastating, and patients suffer from isolation and depression due to stigmatization



## CO-MORBIDITIES

Psoriasis is associated with numerous serious, debilitating and sometimes chronic comorbidities.



30% of patients are diagnosed with Psoriatic arthritis



46%

Patients have an increased risk for type 2 diabetes, and those with severe psoriasis were 46 percent more likely to have type 2 diabetes.



58%

People with severe psoriasis are 58 percent more likely to have a major cardiac event and 43 percent more likely to have a stroke.



25%

Approximately 25% of patients report psychological comorbidities such as stress, anxiety and depression.

## SOCIO-ECONOMIC IMPACT

The life expectancy of patients is approximately 10 years lower than the general population

Total annual cost of psoriasis in the USA was estimated to be \$11.25 billion

Lost productivity costs (leaving work earlier than usual, absence due to illness and loss of leisure time) have been found to account for 22-43% of the mean annual cost of psoriasis

One in four people experience that it is harder to get work if you have psoriasis


Patients would choose an approximately 50% lower life expectancy to be free of the disease for the rest of their lives

## TREATMENTS

Although there is no cure for psoriasis, it is treatable.

Many different therapies are available that reduce symptoms, restore patients' self-confidence and improve quality of life.

There is still a need for new innovative medicines for the treatment of psoriasis.



### TOPICAL THERAPY

- Fixed combination of betamethasone dipropionate and calcipotriol
- Vitamin D3 analogues
- Steroids
- Retinoids
- Dithranol

### PHOTOTHERAPY (plus retinoids)

- PUVA (Systemic, local)
- UVB (311 nm)
- UVA/UVB

### SYSTEMIC THERAPY

- Biologicals
- Cyclosporine A
- Methotrexate
- Fumaric acid esters

Mild Psoriasis  
52% of patients

Moderate Psoriasis  
36% of patients

Severe Psoriasis  
12% of patients